Jacob S. Bowers

Jacob S. Bowers

Auto-generated profile, based on publicly available information

Jacob S. Bowers

Medical University of South Carolina

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2017 in Science Immunology
Verified
Journal Article
Closed access
PDF file
BMBrian T. Malik
Brian T. Malik
KBKatelyn T. Byrne
Katelyn T. Byrne
JVJennifer L. Vella
Jennifer L. Vella
PZPeisheng Zhang
Peisheng Zhang
TSTamer B. Shabaneh
Tamer B. Shabaneh
MTMary Jo Turk
Mary Jo Turk
Tissue-resident memory T (TRM) cells have been widely characterized in infectious disease settings; however, their role in mediating immunity to cancer remains unknown. We report that skin-resident memory T cell responses to melanoma are generated naturally as a result of autoimmune vitiligo. Melanoma antigen–specific TRM cells resided predominantly in melanocyte-depleted hair follicles and were maintained without recirculation or replenishment from the lymphoid compartment. These cells expressed CD103, CD69, and CLA (cutaneous lymphocyte antigen), but lacked PD-1 (programmed cell death protein–1) or LAG-3 (lymphocyte activation gene–3), and were capable of making IFN-γ (interferon-γ). CD103 expression on CD8 T cells was required for the establishment of TRM cells in the skin but was dispensable for vitiligo development. CD103+ CD8 TRM cells were critical for protection against melanoma rechallenge. This work establishes that CD103-dependent TRM cells play a key role in perpetuating antitumor immunity.

6 December 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
SBStefanie R. Bailey
Stefanie R. Bailey
MNMichelle H. Nelson
Michelle H. Nelson
KMKinga Majchrzak-Kuligowska
Kinga Majchrzak-Kuligowska
JBJacob S. Bowers
Jacob S. Bowers
MWMegan M. Wyatt
Megan M. Wyatt
CPChrystal M. Paulos
Chrystal M. Paulos
CD8+T lymphocytes mediate potent immune responses against tumor, but the role of human CD4+T cell subsets in cancer immunotherapy remains ill-defined. Herein, we exhibit that CD26 identifies three T helper subsets with distinct immunological properties in both healthy individuals and cancer patients. Although CD26negT cells possess a regulatory phenotype, CD26intT cells are mainly naive and CD26highT cells appear terminally differentiated and exhausted. Paradoxically, CD26highT cells persist in and regress multiple solid tumors following adoptive cell transfer. Further analysis revealed that CD26highcells have a rich chemokine receptor profile (including CCR2 and CCR5), profound cytotoxicity (Granzyme B and CD107A), resistance to apoptosis (c-KIT and Bcl2), and enhanced stemness (β-catenin and Lef1). These properties license CD26highT cells with a natural capacity to traffic to, regress and survive in solid tumors. Collectively, these findings identify CD4+T cell subsets with properties critical for improving cancer immunotherapy.

29 September 2017 in Frontiers in Immunology
Verified
Journal Article
Open access
JBJacob S. Bowers
Jacob S. Bowers
KMKinga Majchrzak-Kuligowska
Kinga Majchrzak-Kuligowska
MNMichelle H. Nelson
Michelle H. Nelson
BABulent Arman Aksoy
Bulent Arman Aksoy
MWMegan M. Wyatt
Megan M. Wyatt
CPChrystal M. Paulos
Chrystal M. Paulos
Phosphatidylinositol-3-kinase p110δ (PI3Kδ) inhibition by Idelalisib (CAL-101) in hematological malignancies directly induces apoptosis in cancer cells and disrupts immunological tolerance by depleting regulatory T cells (Tregs). Yet, little is known about the direct impact of PI3Kδ blockade on effector T cells from CAL-101 therapy. Herein, we demonstrate a direct effect of p110δ inactivation via CAL-101 on murine and human CD8+ T cells that promotes a strong undifferentiated phenotype (elevated CD62L/CCR7, CD127 and Tcf7). These CAL-101 T cells also persisted longer after transfer into tumor bearing mice in both the murine syngeneic and human xenograft mouse models. The less differentiated phenotype and improved engraftment of CAL-101 T cells resulted in stronger antitumor immunity compared to traditionally expanded CD8+ T cells in both tumor models. Thus, this report describes a novel direct enhancement of CD8+ T cells by a p110δ inhibitor that leads to markedly improved tumor regression. This finding has significant implications to improve outcomes from next generation cancer immunotherapies.

9 March 2017 in JCI Insight
Verified
Journal Article
Open access
PDF file
JBJacob S. Bowers
Jacob S. Bowers
MNMichelle H. Nelson
Michelle H. Nelson
KMKinga Majchrzak-Kuligowska
Kinga Majchrzak-Kuligowska
SBStefanie R. Bailey
Stefanie R. Bailey
BRBärbel Rohrer
Bärbel Rohrer
CPChrystal M. Paulos
Chrystal M. Paulos
Adoptive immunotherapy for solid tumors relies on infusing large numbers of T cells to mediate successful antitumor responses in patients. While long-term rapid-expansion protocols (REPs) produce sufficient numbers of CD8 + T cells for treatment, they also cause decline in the cell’s therapeutic fitness. In contrast, we discovered that IL-17–producing CD4 + T cells (Th17 cells) do not require REPs to expand 5,000-fold over 3 weeks. Also, unlike Th1 cells, Th17 cells do not exhibit hallmarks of senescence or apoptosis, retaining robust antitumor efficacy in vivo. Three-week-expanded Th17 cells eliminated melanoma as effectively as Th17 cells expanded for 1 week when infused in equal numbers into mice. However, treating mice with large recalcitrant tumors required the infusion of all cells generated after 2 or 3 weeks of expansion, while the cell yield obtained after 1-week expansion was insufficient. Long-term-expanded Th17 cells also protected mice from tumor rechallenge including lung metastasis. Importantly, 2-week-expanded human chimeric antigen receptor–positive (CAR + ) Th17 cells also retained their ability to regress human mesothelioma, while CAR + Th1 cells did not. Our results indicate that tumor-reactive Th17 cells are an effective cell therapy for cancer, remaining uncompromised when expanded for a long duration owing to their resistance to senescence.

29 January 2016 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
KMKinga Majchrzak-Kuligowska
Kinga Majchrzak-Kuligowska
MNMichelle H. Nelson
Michelle H. Nelson
SBStefanie R. Bailey
Stefanie R. Bailey
JBJacob S. Bowers
Jacob S. Bowers
XYXue-Zhong Yu
Xue-Zhong Yu
CPChrystal M. Paulos
Chrystal M. Paulos

3 July 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
MNMichelle H. Nelson
Michelle H. Nelson
HKHannah Knochelmann
Hannah Knochelmann
SBStefanie R. Bailey
Stefanie R. Bailey
LHLogan W. Huff
Logan W. Huff
JBJacob S. Bowers
Jacob S. Bowers
CPChrystal M. Paulos
Chrystal M. Paulos
Human CD4 + T cell subsets elicit differential immunity against solid tumors when redirected with antigen specificity.